Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
Survival (time to event) data: median survival times | The BMJ
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
TTFields in Unresectable MPM: STELLAR Results in Practice - ILCN.org (ILCN/WCLC)
Kaplan–Meier survival curves. (A) Median overall survival was... | Download Scientific Diagram
GraphPad Prism 10 Statistics Guide - Determining the median followup time
estimation - Estimating median survival times from Kaplan-Meier plot inspection - Cross Validated
Median overall survival of the patients following all o | Open-i
Median Survival Time - an overview | ScienceDirect Topics
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Kaplan-Meier survival analysis
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
Survival Analysis in R
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
